{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:29:01Z","timestamp":1791052141840,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.phrs.2021.105499","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:13:01Z","timestamp":1613560381000},"page":"105499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)"],"prefix":"10.1016","volume":"166","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matjaz","family":"Bunc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Dyrbus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fedacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Gierlotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Jarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Lucia","family":"Magda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Margetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Margoczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Durak-Nalbantic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ostadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Trbusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Alexandru","family":"Udroiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusko","family":"Vulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105499_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","article-title":"European Society of Cardiology: Cardiovascular Disease Statistics 2019","volume":"41","author":"Timmis","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib3","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/eurheartj\/ehaa475","article-title":"Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project","volume":"41","author":"Barbato","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib4","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib5","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105499_bib6","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association","volume":"13","author":"Robinson","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2021.105499_bib8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105499_bib12","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","author":"Schubert","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.phrs.2021.105499_bib14","first-page":"NP1","volume":"2016","author":"Piepoli","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"41","key":"10.1016\/j.phrs.2021.105499_bib15","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"2020","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib16","article-title":"P3400Definition of extremely high cardiovascular risk in patients after acute myocardial infarction \u2013 data from the TERCET Registry","volume":"40","author":"Dyrbus","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: lower is better for longer \u2013 even at low risk","volume":"18","author":"Penson","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2021.105499_bib18","article-title":"How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors","author":"Cybulska","year":"2020","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.phrs.2021.105499_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamacardio.2016.3458","article-title":"Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction","volume":"1","author":"Kureshi","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006537","article-title":"Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology\/European Atherosclerosis Society (ESC\/EAS) guidelines after acute coronary syndromes","volume":"6","author":"Gencer","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2021.105499_bib21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105499_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"39","key":"10.1016\/j.phrs.2021.105499_bib24","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC\/ESH guidelines for the management of arterial hypertension","volume":"2018","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105499_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2021.01.009","article-title":"Lipid-lowering therapies: better together","author":"Banach","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105499_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25675","article-title":"Statins and LDL-C in secondary prevention \u2013 so much progress, so far to go","volume":"3","author":"Banach","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.phrs.2021.105499_bib27","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1080\/14656566.2018.1532501","article-title":"Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?","volume":"19","author":"Franczyk","year":"2018","journal-title":"Expert Opin. Pharmcother."},{"key":"10.1016\/j.phrs.2021.105499_bib28","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","author":"Ray","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib29","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study","author":"Gaudet","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/M17-1566","article-title":"Statin denial: an internet-driven cult with deadly consequences","volume":"167","author":"Nissen","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105499_bib31","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jcsm.12344","article-title":"Introducing the \u2018Drucebo\u2019 effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions","volume":"9","author":"Penson","year":"2018","journal-title":"J. Cachex Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.phrs.2021.105499_bib32","doi-asserted-by":"crossref","DOI":"10.5114\/aoms\/132304","article-title":"Drucebo effect \u2013 the challenge we should all definitely face!","volume":"17","author":"Banach","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2021.105499_bib33","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/1381612820666141013134447","article-title":"Adverse effects of statins \u2013 myths and reality","volume":"21","author":"\u0160imi\u0107","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.phrs.2021.105499_bib34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/HCO.0000000000000519","article-title":"Statin loading in cardiovascular surgery: never too early to treat","volume":"33","author":"Katsiki","year":"2018","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5603\/KP.a2019.0038","article-title":"Comprehensive coordinated care after myocardial infarction (KOSZawal): a patient\u2019s perspective","volume":"77","author":"Feusette","year":"2019","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.phrs.2021.105499_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5114\/aoms.2019.85649","article-title":"Managed care after acute myocardial infarction (KOS-zawal) reduces major adverse cardiovascular events by 45% in 3-month follow-up \u2013 single-center results of Poland\u2019s National Health Fund program of comprehensive post-myocardial infarction care","volume":"16","author":"Wita","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2021.105499_bib37","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"16","key":"10.1016\/j.phrs.2021.105499_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/aoms.2020.93253","article-title":"Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders","volume":"2020","author":"Solnica","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2021.105499_bib39","article-title":"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial","author":"Diaz","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2021.105499_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2021.105499_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz747.0310","article-title":"P705Step by step diagnosis and management of statin intolerance: position paper from an International Lipid Expert Panel","volume":"40","author":"Penson","year":"2019","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.phrs.2021.105499_bib42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.phrs.2021.105499_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran \u2013 new hope in the management of lipid disorders?","volume":"14","author":"Dyrbu\u015b","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2021.105499_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2020.09.028","article-title":"Why might visit to visit variability of lipoproteins have an effect on cardiovascular diseasees?","volume":"312","author":"Reiner","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105499_bib45","unstructured":"Recommendations of the Discharge Letter for ACS patients according to the Czech Acute Cardiac Care Association. (Accessed 30 January 2021)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:21:46Z","timestamp":1760912506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":45,"alternative-id":["S1043661821000839"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105499","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105499"}}